IRMDNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

IRADIMED CORP

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026

$87.65−0.62 (-0.70%)

Close on Oct 19, 2026

Market cap: $1.13B
P/E (TTM): 49.0
Dividend yield: –

IRADIMED CORP income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31
Revenue	84	73	66	53	42	32	39	30	23	32	32	16	11
Cost of Revenue	19	17	15	12	9.76	8.14	8.82	7.21	5.57	6.15	5.84	3.40	2.85
Gross Profit	64	56	50	41	32	24	30	23	18	26	26	12	8.49
Research & Development	2.98	2.83	2.86	2.28	1.91	1.90	1.43	1.52	1.72	1.35	1.76	1.07	1.01
Selling, General & Admin	35	32	27	23	20	22	20	16	15	14	12	8.11	4.69
Selling & Marketing	17	16	12	13	11	10	9.17	7.00	5.50	5.28	4.71	3.30	2.30
General & Administrative	18	16	15	11	9.77	12	10	8.71	9.00	8.80	7.77	4.82	2.39
Advertising Expenses	–	–	–	–	0.10	0.01	0.16	0.12	0.12	0.14	0.07	0.07	0.08
Operating Expenses	38	34	30	26	22	24	21	17	16	15	14	9.18	5.70
Operating Income	26	22	20	16	9.82	-0.76	8.65	6.00	1.29	11	12	3.07	2.79
Interest & Investment Income	2.01	2.19	1.86	0.58	0.03	0.13	0.39	0.24	0.12	0.13	0.15	0.01	–
Other Non-Operating Income	2.21	2.31	1.70	0.55	0.02	0.14	0.40	0.19	0.11	0.03	0.12	-0.05	0.00
Gain (Loss) on Investments	–	–	–	0.01	0.02	0.02	0.01	-0.03	-0.01	-0.08	0.00	–	–
Gain (Loss) on Sale of Assets	0.20	0.00	-0.01	0	-0.01	-0.01	–	–	–	–	–	–	–
Pretax Income	28	24	22	16	9.84	-0.62	9.04	6.20	1.40	11	12	3.02	2.78
Income Tax Expense	5.88	5.04	4.55	3.35	0.51	-1.99	-0.59	-0.11	0.90	3.74	4.10	0.97	0.85
Net Income incl. Noncontrolling Interests	22	19	17	13	9.33	1.37	9.63	6.30	0.50	7.21	–	–	–
Net Income	22	19	17	13	9.33	1.37	9.63	6.30	0.50	7.21	7.53	2.05	1.94
EPS (Basic)(per share)	1.77	1.52	1.36	1.02	0.76	0.11	0.85	0.59	0.05	0.67	0.68	0.23	0.28
EPS (Diluted)(per share)	1.75	1.50	1.35	1.02	0.74	0.11	0.78	0.52	0.04	0.60	0.60	0.20	0.22
Shares Outstanding (Basic, Weighted)(shares)	13	13	13	13	12	12	11	11	11	11	11	8.74	7.00
Shares Outstanding (Diluted, Weighted)(shares)	13	13	13	13	13	12	12	12	12	12	13	10	8.62
EBITDA	27	23	21	16	11	0.58	9.89	7.11	2.59	12	12	3.21	2.93

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 75.9%
Operating margin: 31.9%
Net margin: 26.7%
Return on equity, FY2025: 24.8%

Financial strength

Current ratio: 9.46
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 644.7%

Valuation

P/E ratio: 49.0
Price to sales: 13.07
Price to book: 11.09
Dividend yield: –